Key result
Low-dose prasugrel premedication significantly decreased the risk of periprocedural thromboembolism compared to clopidogrel (HR 0.17; 95% CI 0.03-0.99).
Why the study?
Does low-dose prasugrel reduce periprocedural thromboembolism and bleeding compared to clopidogrel-based tailored premedication in patients undergoing endovascular treatment of cerebral aneurysms?
Cohort (n=411)
Does low-dose prasugrel reduce periprocedural thromboembolism and bleeding compared to clopidogrel-based tailored premedication in patients undergoing endovascular treatment of cerebral aneurysms?
Hazard Ratio: 0.17 (95% CI 0.03–0.99)
Absolute Event Rate: 0.44% vs 3.76%
Low-dose prasugrel premedication significantly reduces antiplatelet resistance and periprocedural thromboembolic events compared to tailored clopidogrel in patients undergoing endovascular treatment for unruptured cerebral aneurysms.
No takes yet. Share an insight, caveat, or question.
Low-dose prasugrel was associated with lower thromboembolism risk in aneurysm embolization; hypothesis-generating and should not yet change practice.
Cho et al. (2018) conducted a cohort in unruptured cerebral aneurysms (n=411). Low-dose prasugrel vs. Clopidogrel-based tailored antiplatelet was evaluated on thromboembolism (HR 0.17, 95% CI 0.03-0.99). Low-dose prasugrel premedication significantly decreased the risk of periprocedural thromboembolism compared to clopidogrel (HR 0.17; 95% CI 0.03-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: